Literature DB >> 31656439

Acute motor-sensory axonal neuropathy associated with systemic lupus erythematosus.

Smathorn Thakolwiboon1, Amputch Karukote1, Gyeongmo Sohn1.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organs and is generally treated by immunosuppressive agents. Acute motor-sensory axonal neuropathy (AMSAN) is a variant of Guillain-Barré syndrome. The standard therapies are intravenous immunoglobulin or plasmapheresis. An association between AMSAN and SLE is rarely reported. Herein, we describe a case of a 72-year-old man who presented with rapidly progressive paraparesis, dysesthesia, and joint pain with morning stiffness. Initially, he was diagnosed with AMSAN. Intravenous immunoglobulin was given without significant improvement. Subsequent studies indicated the diagnosis of SLE. Therefore, the patient was treated with intravenous methylprednisolone, cyclophosphamide, and then plasmapheresis. At 3 months, he improved from bedridden to wheelchair-bound. Our case demonstrates AMSAN as a rare initial manifestation that can lead to significant disability.
© 2019 Baylor University Medical Center.

Entities:  

Keywords:  AMSAN; Acute motor-sensory axonal neuropathy; Guillain-Barré syndrome; systemic lupus erythematosus

Year:  2019        PMID: 31656439      PMCID: PMC6793991          DOI: 10.1080/08998280.2019.1647715

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  18 in total

Review 1.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  James J Sejvar; Katrin S Kohl; Jane Gidudu; Anthony Amato; Nandini Bakshi; Roger Baxter; Dale R Burwen; David R Cornblath; Jan Cleerbout; Kathryn M Edwards; Ulrich Heininger; Richard Hughes; Najwa Khuri-Bulos; Rudolf Korinthenberg; Barbara J Law; Ursula Munro; Helena C Maltezou; Patricia Nell; James Oleske; Robert Sparks; Priscilla Velentgas; Patricia Vermeer; Max Wiznitzer
Journal:  Vaccine       Date:  2010-06-18       Impact factor: 3.641

2.  Overlap of Bickerstaff encephalitis and Guillain-Barré syndrome in a patient with systemic lupus.

Authors:  Daniel P A Santos; Mariana Spitz; Perola Oliveira; Thiago Barcia; Rafael Souza da Silva; Luiza Lopes de Azevedo; Claudio Meilman; Luiz F Vasconcellos; Clinete Sampaio Lacativa; Jorge Noujaim El-kadum
Journal:  Arq Neuropsiquiatr       Date:  2009-09       Impact factor: 1.420

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  Plasma exchange for Guillain-Barré syndrome.

Authors:  Sylvie Chevret; Richard Ac Hughes; Djillali Annane
Journal:  Cochrane Database Syst Rev       Date:  2017-02-27

5.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

6.  Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis.

Authors:  Avraham Unterman; Johannes E S Nolte; Mona Boaz; Maya Abady; Yehuda Shoenfeld; Gisele Zandman-Goddard
Journal:  Semin Arthritis Rheum       Date:  2010-10-20       Impact factor: 5.532

Review 7.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Anthony V Swan; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 8.  Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update.

Authors:  Antonino Uncini; Satoshi Kuwabara
Journal:  Clin Neurophysiol       Date:  2012-04-04       Impact factor: 3.708

9.  Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.

Authors: 
Journal:  Lancet       Date:  1993-03-06       Impact factor: 79.321

10.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

Authors:  R van Koningsveld; P I M Schmitz; F G Avander Meché; L H Visser; J Meulstee; P A van Doorn
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

View more
  2 in total

Review 1.  Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases.

Authors:  Delia Tulbă; Bogdan Ovidiu Popescu; Emilia Manole; Cristian Băicuș
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

2.  Case Report: Guillain-Barré Syndrome as Primary Presentation of Systemic Lupus Erythematosus (SLE-GBS) in a Teenage Girl.

Authors:  Elham Beshir; Ernestina Belt; Nidheesh Chencheri; Aqdas Saqib; Marco Pallavidino; Ulrich Terheggen; Abdalla Abdalla; Leal Herlitz; Elsadeg Sharif; Martin Bitzan
Journal:  Front Pediatr       Date:  2022-03-17       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.